Please provide your email address to receive an email when new articles are posted on . Renin-angiotensin-aldosterone system inhibitor use in patients with hypertension and intracranial aneurysm was ...

A recent study posted to the medRxiv* preprint server investigated the association of renin-angiotensin-aldosterone system (RAAS)-mediated hypertension (HT) with coronavirus disease 2019 (COVID-19).

Treatments that target the renin-angiotensin-aldosterone system (RAAS) don’t improve outcomes in adult patients hospitalized with acute COVID-19. Three separate trials of different RAAS-related ...

At one time, dual RAAS blockade was expected to provide more-complete inhibition of RAAS among patients with DKD. Results of large clinical trials dashed these hopes, finding increased risk of AKI and ...

RAAS inhibitors in MASLD are linked to reduced liver cancer risk in a Taiwan study. Learn more about the findings and clinical implications.

In a recent study posted to the medRxiv* preprint server, researchers conducted an umbrella review and meta-analysis of the renin-angiotensin-aldosterone system (RAAS) inhibitors' impact on ...

Discontinuation of RAAS inhibitors is often the first approach to manage hyperkalemia. Discontinuation of renin–angiotensin-aldosterone system (RAAS) inhibitors after the first hyperkalemia episode ...

Please provide your email address to receive an email when new articles are posted on . Many international medical societies have endorsed the continuation of renin-angiotensin-aldosterone system ...